Unlike some countries that have “flattened the curve,” the U.S. is experiencing a sharp rise in COVID-19 cases. In this video – part of a series on the scientific and investment implications of COVID-19 – Biotech Analyst Agustin Mohedas explains why the U.S. trajectory has diverged, noting how the outbreak’s dynamics are changing and what that could mean for the next phase of the pandemic.

Key Takeaways

  • COVID-19 case numbers are rising in the U.S., even as many other countries have successfully “flattened the curve.” One reason may be a lack of coordinated response to the disease in the U.S. and the decision to reopen economies despite comparatively high active case counts.
  • That said, hospitalization rates have declined as the average age of the newly infected skews younger. In addition, doctors and nurses now have better knowledge of how to treat the disease, helping survivability rates.
  • Large infection numbers could also make it easier for drug makers to find enough patients for testing potential vaccines, some of which are moving into late-stage clinical trials.